Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
13,201
Total Claims
$1.7M
Drug Cost
689
Beneficiaries
$2,476
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
-85%
Opioid rate vs peers
0.3% vs 2.2% avg
+75%
Cost per patient vs peers
$2,476 vs $1,411 avg
+20%
Brand preference vs peers
12.8% vs 10.6% avg
Opioid Prescribing
0.3%
Opioid Rate
43
Opioid Claims
$228
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 1,666 claims · $1.5M
Generic: 11,390 claims · $240K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Dulaglutide | 113 | $184K |
| Semaglutide | 98 | $160K |
| Dapagliflozin Propanediol | 71 | $98K |
| Empagliflozin | 70 | $87K |
| Tirzepatide | 52 | $82K |
| Sitagliptin Phosphate | 56 | $78K |
| Linaclotide | 59 | $66K |
| Apixaban | 39 | $60K |
| Insulin Degludec | 57 | $51K |
| Mirabegron | 53 | $50K |
| Budesonide/Formoterol Fumarate | 71 | $47K |
| Sitagliptin Phos/Metformin Hcl | 40 | $43K |
| Insulin Glargine,hum.Rec.Anlog | 50 | $31K |
| Insulin Glargine,hum.Rec.Anlog | 26 | $27K |
| Evolocumab | 15 | $25K |
Prescribing Profile
Patient Profile
73
Avg Age
50%
Female
1.39
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data